About

About ACRO Biomedical Co., Ltd. ACRO Biomedical develops and produces biomaterial medical devices for human tissue engineering and regenerative medicine (TERM). ACRO Biomedical uses its proprietary supercritical CO₂ extraction technology to remove cells, fat and non-collagenous proteins from animal tissues, while keeping the undiminished collagen scaffold as the biomaterial for high-end medical devices in the medical regenerative field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular and neural surgery, etc. About ACRO Biomedical Co., Ltd. ACRO Biomedical develops and produces biomaterial medical devices for human tissue engineering and regenerative medicine (TERM). ACRO Biomedical uses its proprietary supercritical CO₂ extraction technology to remove cells, fat and non-collagenous proteins from animal tissues, while keeping the undiminished collagen scaffold as the biomaterial for high-end medical devices in the medical regenerative field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular and neural surgery, etc. ACRO Biomedical develop and produce biomaterial medical devices for human tissue engineering and regenerative medicine. We use our proprietary supercritical CO₂ extraction technology to remove cells, fat, and non-collagenous proteins from animal tissues, while keeping the undiminished collagen scaffold as the biomaterial for high-end medical devices in the medical regenerative field. Established in June 2014, ACRO Biomedical Co., Ltd. is a biotechnology company specializing in developing and manufacturing biomaterial-based medical devices for tissue engineering and regenerative medicine. The company’s core technology utilizes proprietary supercritical carbon dioxide (ScCO₂) extraction to remove cells, lipids, and non-collagenous proteins from animal tissues, while preserving the native collagen scaffolds. These decellularized scaffolds are used in advanced applications across wound care, orthopedics, dentistry, ophthalmology, cardiovascular and neural surgery, aesthetic microsurgery, and more. One of ACRO Biomedical’s key innovations, ABCcolla® Collagen Ophthalmic Matrix, has obtained medical device approval from Taiwan’s Ministry of Health and Welfare for clinical ophthalmic use. Globally, ACRO Biomedical holds 93 patents and has secured 42 medical device approvals in numerous countries, including the United States (FDA), Taiwan, India, Singapore, and several others, with expansion into additional markets actively underway. With a long-term goal of enabling whole-organ engineering for heart, liver, and kidney transplantation, ACRO Biomedical is advancing the science of in vivo recellularization, aiming to develop transplantable, patient-specific organs. The company remains committed to delivering safe, innovative, and clinically impactful solutions for the future of regenerative medicine.